Current approaches to the diagnosis and treatment of cholangiocarcinoma

Current Gastroenterology Reports

Volumn 8, Issue 1, 2006, Pages 30-37

  Reddy, Santosh B ^b   Patel, Tushar ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CA 195 ANTIGEN; CA 50 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERFERON; MITOMYCIN; PORPHYRIN;

BILE DUCT CARCINOMA; BILIARY TRACT ENDOSCOPY; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHOLANGIOGRAPHY; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; ENDOSCOPIC ECHOGRAPHY; HEPATOJEJUNOSTOMY; HISTOPATHOLOGY; HUMAN; LAPAROSCOPIC SURGERY; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATICODUODENECTOMY; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURGICAL TECHNIQUE;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DIGESTIVE SYSTEM SURGICAL PROCEDURES; HUMANS; NEOPLASM STAGING; PALLIATIVE CARE; PHOTOCHEMOTHERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 33645081225     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-006-0061-1     Document Type: Review

References (51)

1. Lazaridis KN, Gores GJ: Cholangiocarcinoma. Gastroenterology 2005, 128:1655-1667.
2. Shaib YH, El-Serag HB, Davila JA, et al.: Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005, 128:620-626.
3. Jarnagin WR, Fong Y, DeMatteo RP, et al.: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001, 234:507-517.
4. Patel AH, Harnois DM, Klee GG, et al.: The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:204-207.
5. Lindberg B, Arnelo U, Bergquist A, et al.: Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis. Endoscopy 2002, 34:909-916.
6. Siqueira E, Schoen RE, Silverman W, et al.: Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc 2002, 56:40-47.
7. Ramage JK, Donaghy A, Farrant JM, et al.: Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995, 108:865-869.
8. Bjornsson E, Kilander A, Olsson R: CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 1999, 19:501-508.
9. Nehls O, Gregor M, Klump B: Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004, 24:139-154.
10. Bloom CM, Langer B, Wilson SR: Role of US in the detection, characterization, and staging of cholangiocarcinoma. Radiographics 1999, 19:1199-1218.
11. Tillich M, Mischinger HJ, Preisegger KH, et al.: Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma. AJR Am J Roentgenol 1998, 171:651-658.
12. Manfredi R, Barbaro B, Masselli C, et al.: Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis 2004, 24:155-164.
13. Zidi SH, Prat F, Le Guen O, et al.: Performance characteristics of magnetic resonance cholangiography in the staging of malignant hilar strictures. Gut 2000, 46:103-106.
14. Sugiyama M, Hagi H, Atomi Y, Saito M: Diagnosis of portal venous invasion by pancreatobiliary carcinoma: value of endoscopic ultrasonography. Abdom Imaging 1997, 22:434-438.
15. Tamada K, Ueno N, Tomiyama T, et al.: Characterization of biliary strictures using intraductal ultrasonography: comparison with percutaneous cholangioscopic biopsy. Gastrointest Endosc 1998, 47:341-349.
16. Kim YJ, Yun M, Lee WJ, et al.: Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2003, 30:1467-1472.
17. Anderson CD, Rice MH, Pinson CW, et al.: Fluorodeoxy-glucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004, 8:90-97.
18. Schoefl R, Haefner M, Wrba F, et al.: Forceps biopsy and brush cytology during endoscopic retrograde cholangiopancreatography for the diagnosis of biliary stenoses. Scand J Gastroenterol 1997, 32:363-368.
19. Selvaggi SM: Biliary brushing cytology. Cytopathology 2004, 15:74-79.
20. Farrell RJ, Jain AK, Brandwein SL, et al.: The combination of stricture dilation, endoscopic needle aspiration, and biliary brushings significantly improves diagnostic yield from malignant bile duct strictures. Gastrointest Endosc 2001, 54:587-594.
21. Sirica AE: Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005, 41:5-15.
22. Itoi T, Shinohara Y, Takei K, et al.: Detection of telomerase activity in biopsy specimens for diagnosis of biliary tract cancers. Gastrointest Endosc 2000, 52:380-386.
23. Kipp BR, Stadheim LM, Halling SA, et al.: A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 2004, 99:1675-1681.
24. Yang B, House MC, Guo M, et al.: Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol 2005, 18:412-420.
25. Tsao JI, Nimura Y, Kamiya J, et al.: Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Ann Surg 2000, 232:166-174.
26. Nakeeb A, Pitt HA, Sohn TA, et al.: Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996, 224:463-473.
27. Burke EC, Jarnagin WR, Hochwald SN, et al.: Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998, 228:385-394.
28. Kitagawa Y, Nagino M, Kamiya J, et al.: Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg 2001, 233:385-392.
29. Okabayashi T, Yamamoto J, Kosuge T, et al.: A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001, 92:2374-2383.
30. Chamberlain RS, Blumgart LH: Hilar cholangiocarcinoma: a review and commentary. Ann Surg Oncol 2000, 7:55-66.
31. Connor S, Barron E, Wigmore SJ, et al.: The utility of laparoscopic assessment in the preoperative staging of suspected hilar cholangiocarcinoma. J Gastrointest Surg 2005, 9:476-480.
32. Di Stefano DR, de Baere T, Denys A, et al.: Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. Radiology 2005, 234:625-630.
33. Jarnagin WR, Shoup M: Surgical management of cholangiocarcinoma. Semin Liver Dis 2004, 24:189-199.
34. Cherqui D, Benoist S, Malassagne B, et al.: Major liver resection for carcinoma in jaundiced patients without preoperative biliary drainage. Arch Surg 2000, 135:302-308.
35. Serafini FM, Sachs D, Bloomston M, et al.: Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg 2001, 67: 839-843.
36. Pitt HA, Nakeeb A, Abrams RA, et al.: Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 1995, 221:788-797.
37. McMasters KM, Tuttle TM, Leach SD, et al.: Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997, 174:605-608.
38. Meyer CG, Penn I, James L: Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000, 69:1633-1637.
39. Heimbach JK, Gores GJ, Haddock MG, et al.: Liver transplantation for unresectable perihilar-cholangiocarcinoma. Semin Liver Dis 2004, 24:201-207.
40. Vauthey JN, Blumgart LH: Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994, 14:109-114.
41. De Palma GD, Galloro G, Siciliano S, et al.: Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001, 53:547-553.
42. Washburn WK, Lewis WD, Jenkins RL: Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995, 130:270-276.
43. Hejna M, Pruckmayer M, Raderer M: The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 1998, 34:977-986.
44. Harvey JH, Smith UP, Schein PS: 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984, 2:1245-1248.
45. Cantore M, Mambrini A, Fiorentini G, et al.: Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer 2005, 103:1402-1407.
46. Patt YZ, Jones DV Jr, Hoque A, et al.: Phase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 1996, 14:2311-2315.
47. Malik IA, Aziz Z, Zaidi SH, Sethuraman C: Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol 2003, 26:174-177.
48. Knox JJ, Hedley D, Oxa A, et al.: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005, 23:2332-2338.
49. Burger I, Hong K, Schulick R, et al.: Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005, 16:353-361.
50. Ortner ME, Caca K, Berr F, et al.: Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003, 125:1355-1363.
51. Khan SA, Davidson BR, Goldin R, et al.: Guidelines for the diagnosis and treatment of cholangiocarcinoma: a consensus document. Gut 2002, 51(Suppl 6):VL1-VL-9.